ReviewJAMA oncology2023
Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Narrative Review.
Review in JAMA oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Biomarkers Associated With Extranodal Extension (ENE) in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Systematic Review.Head & neck · 2026Pooled it
- Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.Oral oncology · 2025Pooled it
- Cell-free HPV-DNA as a high-accuracy biomarker for treatment de-escalation in HPV-positive head and neck squamous cell carcinoma.Frontiers in oncology · 2025Pooled it
- The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma: systematic review and meta-analysis.Journal of experimental & clinical cancer research : CR · 2024Pooled it
- Application of artificial intelligence in head and neck squamous cell carcinoma.Annals of medicine · 2026Review
- The Burden and Risk Factors of Head and Neck Cancers in G20 Countries, 1990-2023.International dental journal · 2026Article
- Validation of MyHPVscore: A High-Performance Human Papillomavirus Circulating Tumor DNA Laboratory-Developed Test.The Journal of molecular diagnostics : JMD · 2026Article
- Blood plasma and oral rinse liquid profiling for human papillomavirus in head and neck cancer - Unmasking false-positive p16 tissue cases and tracking disease dynamics.Journal of translational medicine · 2026Article
- Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Liquid Biopsies in HNSCC: Current Landscape and Emerging Opportunities in the Era of HPV Stratification.International journal of molecular sciences · 2026Review
- Circulating Tumor HPV DNA Kinetics for Squamous Cell Carcinoma of the Lacrimal Sac Treated with Chemoradiotherapy.Head and neck pathology · 2026Article
- NI-RADS in posttreatment head and neck cancer surveillance: a framework for standardized imaging with clinical impact.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection.Journal of the National Cancer Institute · 2026Article
- Circulating cell free HPVDNA in HPV positive head and neck cancer reveals fast responders and early peakers during treatment.Scientific reports · 2025Article
- Clinical validation of an HPV whole genome sequencing assay for molecular residual disease detection in HPV-associated head and neck cancer patients treated with surgery.medRxiv : the preprint server for health sciences · 2025Article
- The Value of Circulating Tumor HPV DNA in Head and Neck Squamous Cell Cancer: A Review.Diagnostics (Basel, Switzerland) · 2025Review
- Salivary and Serum Liquid Biopsy Biomarkers for HPV-Associated Oral and Oropharyngeal Cancer: A Narrative Review.Journal of clinical medicine · 2025Review
- Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.Oral oncology · 2025Article
- Circulating biomarkers in HPV-associated oropharyngeal cancer: Clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance.The journal of liquid biopsy · 2025Review
- Toward a Next-Generation Liquid Biopsy for HPV+ HNSCC: Opportunities, Challenges, and the Road Ahead.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Importance: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma has an overall favorable prognosis, yet a subset of patients will experience devastating disease recurrence. Current surveillance standards for detection of recurrent disease are imperfect. There is growing interest in improving detection of recurrent disease through the use of plasma-based assays able to detect circulating tumor HPV DNA. Observations: Although most circulating tumor HPV DNA assays remain in the research domain, the circulating tumor tissue-modified viral HPV DNA assay became commercially available in the United States in early 2020 and has been increasingly used in the clinical setting. With the rapidly increasing incidence of HPV-positive oropharyngeal squamous cell carcinoma and concomitant expansion of biomarker capabilities for this disease, it is critical to reexamine current posttreatment surveillance practices and to determine whether emerging technologies may be used to improve outcomes for a growing survivor population. However, caution is advised; it is not yet known whether biomarker-based surveillance is truly beneficial, and as is true with any intervention, it has the capacity to cause harm. Conclusions and Relevance: Using Margaret Pepe's classic 5 phases of biomarker development for early detection of cancer as a framework, this article reviews the current state of knowledge, highlights existing knowledge gaps, and suggests research that should be prioritized to understand the association between biomarker-based surveillance and patient outcomes. Specific attention is paid to the commercially available tumor tissue-modified viral HPV DNA assay, given its increasing clinical use. This review may serve as a road map for future research and a guide for clinicians considering its adoption in practice. Enrollment of patients into clinical trials incorporating biomarker-based surveillance should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.